Targeted radiation boosts standard care for lung cancer that has spread a little
NCT ID NCT02417662
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether adding stereotactic ablative radiotherapy (SABR) to standard anti-cancer therapy improves survival for people with non-small cell lung cancer that has spread to only a few spots (oligometastatic). About 140 participants are randomly assigned to receive either standard therapy alone or standard therapy plus radiation to the primary tumor and metastases. The main goal is to see if the combination extends overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Stereotactic ablative radiotherapy (SABR) and conventional radiotherapy
What this could lead to
If successful, adding SABR to standard therapy could improve survival and delay cancer progression for patients with limited metastatic lung cancer.
What could go wrong
This is a mid-stage trial with 140 participants, so results may not apply to all patients. Radiotherapy can cause side effects like fatigue or local tissue damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Addenbrooke's Hospital
Cambridge, United Kingdom
-
BEATSON
Glasgow, United Kingdom
-
Belfast City Hospital
Belfast, United Kingdom
-
Bristol Royal Infirmary
Bristol, United Kingdom
-
Christie Hospital
Manchester, United Kingdom
-
City Hospital
Nottingham, United Kingdom
-
Clatterbridge Cancer Centre
Metropolitan Borough of Wirral, United Kingdom
-
Freeman Hospital
Newcastle, United Kingdom
-
Guy's and St Thomas's Hospital
London, United Kingdom
-
Leicester Royal Infirmary
Leicester, United Kingdom
-
Queen Elizabeth Hospital
Birmingham, United Kingdom
-
Royal Surrey County Hospital
Guildford, United Kingdom
-
Southampton General Hospital
Southampton, United Kingdom
-
St Bart's Hospital
London, United Kingdom
-
St James's University Hospital
Leeds, United Kingdom
-
The James Cook University Hospital
Middlesbrough, United Kingdom
-
The Royal Marsden Hospital
London, United Kingdom
-
UCLH
London, England, United Kingdom
-
Weston Park Hospital
Sheffield, United Kingdom